Sr. Director, Global Head of Health Economics & Outcomes Research (Hybrid-Acton, MA or San Diego, CA) (Acton)

Job SummaryThe Senior Director & Global Head of Health Economics & Outcomes Research (HEOR) / Payer Evidence Generation at Insulet is a strategic leader tasked with defining and communicating the clinical, economic, and humanistic value of the Omnipod portfolio and future innovations. Collaborating with various teams, including regional and local access, Medical Affairs, Clinical Development, commercial strategy, R&D, Digital Health, Commercial, and Government Affairs, this role is pivotal in enhancing payer value evidence and health technology assessment (HTA). Reporting to the VP of Global HEMA, the incumbent will lead a global team of experts in HEOR and real-world evidence (RWE) study design, epidemiology, biostatistics, patient-reported outcomes (PROs), and health economic modeling development and adaptation.

Company OverviewInsulet started in 2000 driven to achieve our mission of enabling our customers to enjoy simplicity, freedom and healthier lives through the use of our Omnipod product platform. In the last two decades we have improved the lives of hundreds of thousands of patients who have insulin-requiring diabetes, by using innovative technology that is wearable, waterproof, and lifestyle accommodating. As market leader in our field, we are on an exciting trajectory of significant further growth and geographic expansion enabling us to reach more patients around the globe.We are looking for highly motivated, performance driven individuals who want to be part of further building our Global Health Economics & Market Access (HEMA) Capability and be at the forefront of our rapidly growing global footprint.We are looking to hire amazing people who are guided by shared values and desire to exceed customer expectations. Our continued success depends on it.Position OverviewThe Senior Director & Global Head of Health Economics & Outcomes Research (HEOR)/ Payer Evidence Generation is a global strategic leader responsible for defining and communicating the clinical, economic, and humanistic value of the Omnipod portfolio and Insulet’s future innovations, in partnership with members of the regional and local access community @ Insulet, Medical Affairs, Clinical Development, commercial strategy, R&D, Digital Health, Commercial, and Government Affairs.The incumbent will report to the VP of Global HEMA and will be the primary authority on payer value evidence and health technology assessment (HTA). They will oversee and lead a global capability/team of experts spanning HEOR/RWE study design and execution, epidemiology and biostats, PROs, and health‑economic modeling development and adaptation.ResponsibilitiesDefine and oversee the execution of Insulet’s global HEOR strategy for current, in-market and future assets across all markets.Build and mature global HEOR capabilities that strengthen Insulet’s leadership in demonstrating the health and economic added value of diabetes innovation and connected care. Ensure HEOR evidence is embedded early in clinical development plans and evolves through launch and lifecycle management.Build, expand and lead/mentor a high‑performing global HEOR team.Manage budgets, vendors, and compliance with HEOR guidelines.Lead enterprise-wide HEOR planning to support optimized, sustainable access and reimbursement/coverage decisions (including HTA reviews) of Insulet assets at value-based prices at launch & during their life cycleOversee the design and execution of high-quality real-world evidence programs, epidemiological studies, burden-of-disease research, indirect comparisons, and PRO strategy to further demonstrate the unmet need in current diabetes care and the comparative clinical, economic and humanistic value of Insulet's current and future assets in addressing that need across our key markets.Oversee and drive the development and selection of economic and patient-reported outcomes (PRO) endpoints and instruments to be included in Insulet trials and Insulet-sponsored effectiveness research projects and real-world evidence (RWE) partnerships to drive differentiation and value perception.Ensure global evidence packages for Insulet assets support the needs of the various payer archetypes and HTA bodies across each of the markets Insulet (will) operate in.Strategically drive the early the economic value assessment and maximization for pipeline assets.Lead/oversee (the team) developing and updating a diverse suite of insights-driven economic models for each of the current and future Insulet solutions/target indications, as part of a set of global access-supporting deliverables developed for each of these assets.Plan and drive HEOR publication planning, submission and acceptance of publications of Insulet HEOR data, in collaboration with other stakeholders in the Insulet access community and medical affairs colleagues.Partner with the global HEMA segment leads, US and regional access teams to embed HEOR evidence into global, regional and local pricing, reimbursement, and access strategies.Oversee the inclusion of relevant HEOR evidence in global value dossiers, AMCP dossiers, payer decks, and HTA submissions.Lead/drive the team of health economists supporting affiliates in adapting economic models for local HTA and reimbursement/coverage approval/payer value demonstration needs.Build relationships with academic partners, HEOR experts, and real‑world data collaborators.Represent Insulet at conferences, expert panels, and policy forums.Effectively communicate and explain the impact of external developments in HTA and HEOR/Payer Evidence Generation-related policies across markets on Insulet business and assess/recommend how to address these effectively.Key Decision RightsHealth Economics modeling development and adaptation strategic direction and tactical execution in collaboration with key internal partners and stakeholders.HEOR Strategy setting and oversight of execution across countriesUS and key market-focused HEOR activity executionHealth Economics and PRO endpoint (and instrument) selection in Insulet trials and Insulet-sponsored effectiveness researchEducation and ExperienceBachelor’s degree in life/health sciences or related discipline, and/or equivalent combination of education and experience.Minimum of 15 years of hands-on leadership experience in a Health Economics and Outcomes Research (HEOR) content-developing role in the life science industry (pharma and/or medtech) or consultancy, ideally at global and/or regional levelDemonstrated understanding of the cardinal HEOR-related deliverables that are required in the different phases in the life cycle of medical technologies while exhibiting creativity and out-of-the-box thinking in the delivery of HE-related activitiesDeep understanding of economic modeling and real‑world data analysis approaches & methodologies and selection criteria for real-world data sources for HEOR-focused analyses across key global marketsProven ability to translate complex evidence into clear value narratives for executives and payersExperience in building and leading high-performing (global) HEOR teams, driving accountability, empowerment, customer centricity and collaboration across functions and teams.Deep understanding of HTA policies, processes and requirements for medical technology in key global markets (e.g. UK) with track record of developing HEOR evidence tailored to/applied in these processes.Strong scientific publication record.PreferredPast or present HEOR-content producing experience in the field of diabetes or cardiovascular diseasesMaster’s DegreePharmD industry backgroundHands-on modeling experienceAdditional InformationThe position is hybrid/in-person at our offices in Acton, MA or London, UK or any EU-based Insulet office, with a preference for a UK or EU-based location.Travel is estimated at 20% but will flex depending on business need.Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable and waterproof Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero finger sticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.Studies have demonstrated the clinical and lifestyle advantages of insulin pump therapy over multiple daily insulin injections (MDI). However, many people still choose MDI therapy largely due to the complexity, cost, and inconvenience of conventional pump technology. The Omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. By breaking down the barriers to insulin pump therapy, Insulet hopes to provide both a superior treatment option and life-long health benefits for people with insulin-requiring diabetes.Insulet was founded in 2000 with the mission to improve the lives of people with diabetes and enable customers to enjoy simplicity, freedom, and healthier lives through innovative technology. The Company’s world headquarters and state-of-the-art automated manufacturing facility are located in Acton, Massachusetts with global offices in the U.K., France, Germany, Netherlands, Canada, Mexico, Australia, and the United Arab Emirates. Omnipod products are available in 24 countries around the world.Insulet recently concluded its seventh consecutive year of 20]]> <